納指ETF廣發：將於2026年8月12日開市起停牌，自2026年8月12日10:30起復牌，停牌期間本基金贖回業務照常辦理。

China NMPA, via priority review, has conditionally approved a Class 1 innovative drug, Tengogetinib tablets (brand Jientai), developed by Yaojie Ankang (Nanjing) Technology Co., Ltd. Indication: adults with advanced, metastatic or unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and an FGFR inhibitor. The approval provides a new treatment option for this defined patient group.

創業板指持續走強，盤中漲逾1%，MLCC概念、創新藥板塊領漲大盤。